Sonia Isbert-Calzado
Barcelona, CT, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Effect of Non-nucleoside Resistance-Associated Mutations on the Effectiveness of Long-Acting Cabotegravir + Rilpivirine Therapy: Insights From the Real-World RELATIVITY Cohort.
Journal: Open forum infectious diseases
Published: June 10, 2026
Trends in Age-Related Health Outcomes in People with HIV in Spain, 2006-2023.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: September 10, 2025
Trends in Age-Related Health Outcomes in People with HIV in Spain, 2006-2023.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: September 10, 2025
Genotyping not required for sustained effectiveness of long-acting cabotegravir plus rilpivirine: evidence from the RELATIVITY cohort.
Journal: AIDS (London, England)
Published: July 02, 2025
Genotyping not required for sustained effectiveness of long-acting cabotegravir plus rilpivirine: evidence from the RELATIVITY cohort.
Journal: AIDS (London, England)
Published: July 02, 2025
Real-world Effectiveness and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Comparison With Other Regimens in People With HIV Starting Therapy With AIDS-Defining Conditions: Results From the CoRIS Cohort-The ACTUAS II Study.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: September 09, 2024
Similar CD4/CD8 Ratio Recovery After Initiation of Dolutegravir Plus Lamivudine Versus Dolutegravir or Bictegravir-Based Three-Drug Regimens in Naive Adults With HIV.
Journal: Frontiers in immunology
Published: February 10, 2022
Showing 1-9 of 9
Last Updated: 09/26/2026